Andrea H Weinberger1, Philip H Smith2, Sharon S Allen3, Kelly P Cosgrove4, Michael E Saladin5, Kevin M Gray6, Carolyn M Mazure7, Cora Lee Wetherington8, Sherry A McKee2. 1. andrea.weinberger@einstein.yu.edu. 2. Department of Psychiatry, Yale University School of Medicine, New Haven, CT; 3. Women's Health Research at Yale, Yale University School of Medicine, New Haven, CT; 4. Department of Family Medicine and Community Health, Medical School, University of Minnesota, Minneapolis, MN; 5. Departments of Psychiatry, Diagnostic Radiology, and Neurobiology, Yale University School of Medicine, New Haven, CT; 6. Departments of Health Sciences and Research and Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC; 7. Department of Psychiatry, Yale University School of Medicine, New Haven, CT; Women's Health Research at Yale, Yale University School of Medicine, New Haven, CT; 8. Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC;
Abstract
INTRODUCTION: To determine the effect of ovarian hormones on smoking, we conducted a systematic review of menstrual cycle effects on smoking (i.e., ad lib smoking, smoking topography, and subjective effects) and cessation-related behaviors (i.e., cessation, withdrawal, tonic craving, and cue-induced craving). METHODS: Thirty-six papers were identified on MEDLINE that included a menstrual-related search term (e.g., menstrual cycle, ovarian hormones), a smoking-related search term (e.g., smoking, nicotine), and met all inclusion criteria. Thirty-two studies examined menstrual phase, 1 study measured hormone levels, and 3 studies administered progesterone. RESULTS: Sufficient data were available to conduct meta-analyses for only 2 of the 7 variables: withdrawal and tonic craving. Women reported greater withdrawal during the luteal phase than during the follicular phase, and there was a nonsignificant trend for greater tonic craving in the luteal phase. Progesterone administration was associated with decreased positive and increased negative subjective effects of nicotine. Studies of menstrual phase effects on the other outcome variables were either small in number or yielded mixed outcomes. CONCLUSIONS: The impact of menstrual cycle phase on smoking behavior and cessation is complicated, and insufficient research is available upon which to conduct meta-analyses on most smoking outcomes. Future progress will require collecting ovarian hormone levels to more precisely quantify the impact of dynamic changes in hormone levels through the cycle on smoking behavior. Clarifying the relationship between hormones and smoking-particularly related to quitting, relapse, and medication response-could determine the best type and timing of interventions to improve quit rates for women.
INTRODUCTION: To determine the effect of ovarian hormones on smoking, we conducted a systematic review of menstrual cycle effects on smoking (i.e., ad lib smoking, smoking topography, and subjective effects) and cessation-related behaviors (i.e., cessation, withdrawal, tonic craving, and cue-induced craving). METHODS: Thirty-six papers were identified on MEDLINE that included a menstrual-related search term (e.g., menstrual cycle, ovarian hormones), a smoking-related search term (e.g., smoking, nicotine), and met all inclusion criteria. Thirty-two studies examined menstrual phase, 1 study measured hormone levels, and 3 studies administered progesterone. RESULTS: Sufficient data were available to conduct meta-analyses for only 2 of the 7 variables: withdrawal and tonic craving. Women reported greater withdrawal during the luteal phase than during the follicular phase, and there was a nonsignificant trend for greater tonic craving in the luteal phase. Progesterone administration was associated with decreased positive and increased negative subjective effects of nicotine. Studies of menstrual phase effects on the other outcome variables were either small in number or yielded mixed outcomes. CONCLUSIONS: The impact of menstrual cycle phase on smoking behavior and cessation is complicated, and insufficient research is available upon which to conduct meta-analyses on most smoking outcomes. Future progress will require collecting ovarian hormone levels to more precisely quantify the impact of dynamic changes in hormone levels through the cycle on smoking behavior. Clarifying the relationship between hormones and smoking-particularly related to quitting, relapse, and medication response-could determine the best type and timing of interventions to improve quit rates for women.
Authors: Matthew J Carpenter; Michael E Saladin; Ashley S Leinbach; Steven D Larowe; Himanshu P Upadhyaya Journal: J Womens Health (Larchmt) Date: 2008-03 Impact factor: 2.681
Authors: Teresa R Franklin; Ronald Ehrman; Kevin G Lynch; Derek Harper; Nathan Sciortino; Charles P O'Brien; Anna Rose Childress Journal: J Womens Health (Larchmt) Date: 2008-03 Impact factor: 2.681
Authors: Robert A Schnoll; Freda Patterson; E Paul Wileyto; Rachel F Tyndale; Neal Benowitz; Caryn Lerman Journal: Pharmacol Biochem Behav Date: 2008-10-31 Impact factor: 3.533
Authors: Alicia M Allen; Nicole P Yuan; Betsy C Wertheim; Laurie Krupski; Melanie L Bell; Uma Nair Journal: Transl Behav Med Date: 2019-07-16 Impact factor: 3.046
Authors: Philip H Smith; Andrew J Bessette; Andrea H Weinberger; Christine E Sheffer; Sherry A McKee Journal: Prev Med Date: 2016-07-26 Impact factor: 4.018
Authors: MacKenzie R Peltier; José M Flores; Philip H Smith; Walter Roberts; Terril L Verplaetse; Kelly E Moore; Robyn Hacker; Lindsay M Oberleitner; Sherry A McKee Journal: Nicotine Tob Res Date: 2020-05-26 Impact factor: 4.244
Authors: Nicole L Tosun; Ann M Fieberg; Lynn E Eberly; Katherine A Harrison; Angela R Tipp; Alicia M Allen; Sharon S Allen Journal: Addiction Date: 2019-06-17 Impact factor: 6.526
Authors: Raina D Pang; Madalyn M Liautaud; Matthew G Kirkpatrick; Jimi Huh; John Monterosso; Adam M Leventhal Journal: Neuropsychopharmacology Date: 2017-09-14 Impact factor: 7.853